Top

Published in:

Open Access 01-12-2024 | NSCLC | Research

Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Authors: Ao Zeng, Yanze Yin, Zhilong Xu, Abudumijiti Abuduwayiti, Fujun Yang, Mohammed Saud Shaik, Chao Wang, Keyi Chen, Chao Wang, Xinyun Fang, Jie Dai

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Emerging data suggested a favorable outcome in advanced non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD) patients treated by immunotherapy. The objective of this study was to investigate the effectiveness of neoadjuvant immunotherapy among NSCLC with COPD versus NSCLC without COPD and explore the potential mechanistic links.

Patients and methods

Patients with NSCLC receiving neoadjuvant immunotherapy and surgery at Shanghai Pulmonary Hospital between November 2020 and January 2023 were reviewed. The assessment of neoadjuvant immunotherapy’s effectiveness was conducted based on the major pathologic response (MPR). The gene expression profile was investigated by RNA sequencing data. Immune cell proportions were examined using flow cytometry. The association between gene expression, immune cells, and pathologic response was validated by immunohistochemistry and single-cell data.

Results

A total of 230 NSCLC patients who received neoadjuvant immunotherapy were analyzed, including 60 (26.1%) with COPD. Multivariate logistic regression demonstrated that COPD was a predictor for MPR after neoadjuvant immunotherapy [odds ratio (OR), 2.490; 95% confidence interval (CI), 1.295–4.912; P = 0.007]. NSCLC with COPD showed a down-regulation of HERV–H LTR-associating protein 2 (HHLA2), which was an immune checkpoint molecule, and the HHLA2^low group demonstrated the enrichment of CD8⁺CD103⁺ tissue-resident memory T cells (TRM) compared to the HHLA2^high group (11.9% vs. 4.2%, P = 0.013). Single-cell analysis revealed TRM enrichment in the MPR group. Similarly, NSCLC with COPD exhibited a higher proportion of CD8⁺CD103⁺TRM compared to NSCLC without COPD (11.9% vs. 4.6%, P = 0.040).

Conclusions

The study identified NSCLC with COPD as a favorable lung cancer type for neoadjuvant immunotherapy, offering a new perspective on the multimodality treatment of this patient population. Down-regulated HHLA2 in NSCLC with COPD might improve the MPR rate to neoadjuvant immunotherapy owing to the enrichment of CD8⁺CD103⁺TRM.

Trial registration

Approval for the collection and utilization of clinical samples was granted by the Ethics Committee of Shanghai Pulmonary Hospital (Approval number: K23-228).

Available only for authorised users

Yi YS, Ban WH, Sohng KY. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer. BMC Cancer. 2018;18(1):1053.CrossRefPubMedPubMedCentral

Zhai R, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest. 2014;145(2):346–53.CrossRefPubMed

Haslam A, Prasad V. Estimation of the percentage of US patients with Cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535.CrossRefPubMedPubMedCentral

Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, et al. The promises and challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020;15(9):1409–24.CrossRefPubMedPubMedCentral

Zhou J, Chao Y, Yao D, Ding N, Li J, Gao L, et al. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. Transl Lung Cancer Res. 2021;10(5):2148–62.CrossRefPubMedPubMedCentral

Noda Y, Shiroyama T, Masuhiro K, Amiya S, Enomoto T, Adachi Y, et al. Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer. Sci Rep. 2022;12(1):8881.CrossRefPubMedPubMedCentral

Takayama Y, Nakamura T, Fukushiro Y, Mishima S, Masuda K, Shoda H. Coexistence of Emphysema with non-small-cell Lung Cancer predicts the therapeutic efficacy of Immune Checkpoint inhibitors. Vivo. 2021;35(1):467–74.CrossRef

Kerdidani D, Magkouta S, Chouvardas P, Karavana V, Glynos K, Roumelioti F, et al. Cigarette smoke-Induced Emphysema exhausts early cytotoxic CD8(+) T cell responses against nascent Lung Cancer cells. J Immunol. 2018;201(5):1558–69.CrossRefPubMed

Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A. 2013;110(24):9879–84.CrossRefPubMedPubMedCentral

10.

Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medavarapu R, et al. Expression, clinical significance, and receptor identification of the newest B7 family Member HHLA2 protein. Clin Cancer Res. 2015;21(10):2359–66.CrossRefPubMed

11.

Li Y, Lv C, Yu Y, Wu B, Zhang Y, Lang Q et al. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: the dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy. J Adv Res. 2022.

12.

Wei Y, Ren X, Galbo PM Jr., Moerdler S, Wang H, Sica RA et al. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021;6(61).

13.

Rieder SA, Wang J, White N, Qadri A, Menard C, Stephens G, et al. B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling. Cell Mol Immunol. 2021;18(6):1503–11.CrossRefPubMed

14.

Cheng H, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, et al. Wide expression and significance of Alternative Immune Checkpoint molecules, B7x and HHLA2, in PD-L1-Negative human lung cancers. Clin Cancer Res. 2018;24(8):1954–64.CrossRefPubMedPubMedCentral

15.

Okla K, Farber DL, Zou W. Tissue-resident memory T cells in tumor immunity and immunotherapy. J Exp Med. 2021;218(4).

16.

Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, de Almeida P et al. Intratumoral CD103 + CD8 + T cells predict response to PD-L1 blockade. J Immunother Cancer. 2021;9(4).

17.

Corgnac S, Malenica I, Mezquita L, Auclin E, Voilin E, Kacher J, et al. CD103(+)CD8(+) T(RM) cells accumulate in tumors of Anti-PD-1-Responder Lung Cancer patients and are tumor-reactive lymphocytes enriched with Tc17. Cell Rep Med. 2020;1(7):100127.CrossRefPubMedPubMedCentral

18.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.CrossRefPubMedPubMedCentral

19.

Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021;596(7870):126–32.CrossRefPubMedPubMedCentral

20.

Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023;29(6):1550–62.CrossRefPubMed

21.

Ma H, Zhang Q, Zhao Y, Zhang Y, Zhang J, Chen G, et al. Molecular and clinicopathological characteristics of Lung Cancer Concomitant Chronic Obstructive Pulmonary Disease (COPD). Int J Chron Obstruct Pulmon Dis. 2022;17:1601–12.CrossRefPubMedPubMedCentral

22.

Zhang Q, Feng X, Hu W, Li C, Sun D, Peng Z, et al. Chronic obstructive pulmonary disease alters the genetic landscape and tumor immune microenvironment in lung cancer patients. Front Oncol. 2023;13:1169874.CrossRefPubMedPubMedCentral

23.

Shin SH, Park HY, Im Y, Jung HA, Sun JM, Ahn JS, et al. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. Int J Cancer. 2019;145(9):2433–9.CrossRefPubMed

24.

Xu L, Li F, Jiang M, Li Z, Xu D, Jing J, et al. Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and changes in expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2023;18:139–53.CrossRefPubMedPubMedCentral

25.

Su Q, Du J, Xiong X, Xie X, Wang L. B7-H7: a potential target for cancer immunotherapy. Int Immunopharmacol. 2023;121:110403.CrossRefPubMed

26.

Zhou QH, Li KW, Chen X, He HX, Peng SM, Peng SR et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020;8(1).

27.

Xia C, Huang W, Chen YL, Fu HB, Tang M, Zhang TL, et al. Coexpression of HHLA2 and PD-L1 on Tumor cells independently predicts the survival of spinal Chordoma patients. Front Immunol. 2021;12:797407.CrossRefPubMed

28.

Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 2018;18(8):485–97.CrossRefPubMed

29.

Palmer WH, Leaton LA, Campos Codo A, Crute B, Roest J, Zhu S, et al. Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells. Sci Immunol. 2023;8(84):eade5343.CrossRefPubMed

30.

Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022;185(16):2918–e3529.CrossRefPubMedPubMedCentral

31.

Tissue-Resident Memory T. Cells underlie Neoadjuvant Immunotherapy Response. Cancer Discov. 2022;12(9):OF2.CrossRef

32.

Virassamy B, Caramia F, Savas P, Sant S, Wang J, Christo SN, et al. Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell. 2023;41(3):585–601. e8.CrossRefPubMed

33.

Liang M, Wang X, Cai D, Guan W, Shen X. Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis. Front Immunol. 2023;14:1119383.CrossRefPubMedPubMedCentral

34.

Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, et al. CD103(+) Tumor-Resident CD8(+) T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma patients and Expand significantly during Anti-PD-1 treatment. Clin Cancer Res. 2018;24(13):3036–45.CrossRefPubMed

35.

Abdeljaoued S, Arfa S, Kroemer M, Ben Khelil M, Vienot A, Heyd B et al. Tissue-resident memory T cells in gastrointestinal cancer immunology and immunotherapy: ready for prime time? J Immunother Cancer. 2022;10(4).

36.

Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, et al. Impaired tumor-infiltrating T cells in patients with chronic obstructive Pulmonary Disease Impact Lung Cancer response to PD-1 blockade. Am J Respir Crit Care Med. 2018;198(7):928–40.CrossRefPubMed

37.

Mark NM, Kargl J, Busch SE, Yang GHY, Metz HE, Zhang H, et al. Chronic obstructive Pulmonary Disease alters Immune Cell Composition and Immune checkpoint inhibitor efficacy in Non-small Cell Lung Cancer. Am J Respir Crit Care Med. 2018;197(3):325–36.CrossRefPubMedPubMedCentral

38.

Corleis B, Cho JL, Gates SJ, Linder AH, Dickey A, Lisanti-Park AC, et al. Smoking and human immunodeficiency virus 1 infection promote Retention of CD8(+) T cells in the Airway Mucosa. Am J Respir Cell Mol Biol. 2021;65(5):513–20.CrossRefPubMedPubMedCentral

Title: Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)
Authors: Ao Zeng
Yanze Yin
Zhilong Xu
Abudumijiti Abuduwayiti
Fujun Yang
Mohammed Saud Shaik
Chao Wang
Keyi Chen
Chao Wang
Xinyun Fang
Jie Dai
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: NSCLC
NSCLC
Chronic Obstructive Lung Disease
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12137-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2024

m1A regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma

Prognostic value of creatine kinase (CK)-MB to total-CK ratio in colorectal cancer patients after curative resection

Retraction Note: Haplotype analysis on correlation between transcription factor 7-like 2 gene polymorphism and breast cancer risk

Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets

Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients

Correction: Clinical features and imaging examination assessment of cervical lymph nodes for thyroid carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer